Semaglutide vs Testosterone for weight loss
Short answer: For weight loss, more users report improvement with Testosterone — 93% of 45 reports, versus 84% of 129 for Semaglutide.
Semaglutide has 421 meta-analyses and 307 randomized trials on PubMed; Testosterone has 75 and 125.
Based on 314 reports about Semaglutide and 822 about Testosterone. Not medical advice.
| Semaglutide Medication | Testosterone Medication | |
|---|---|---|
| User score | 64 | 54 |
| Verdict | Mostly positive | Mostly positive |
| Positive of reports that state an outcome | 64% | 77% |
| Reports | 314 | 822 |
| Research | AResearch: Strong | AResearch: Strong |
| Meta-analyses / RCTs | 421 / 307 | 75 / 125 |
| Mainly used for | ||
| Weight loss % reporting improvement | 84% (129) | 93% (45) |
| Appetite % reporting improvement | 83% (64) | — |
| Focus % reporting improvement | 60% (5) | 82% (28) |
| Energy % reporting improvement | 39% (23) | 92% (76) |
| Sleep % reporting improvement | 50% (4) | 79% (19) |
| Anxiety % reporting improvement | — | 80% (25) |
| Mood % reporting improvement | 27% (11) | 88% (104) |
| Memory % reporting improvement | — | 100% (2) |
| Performance % reporting improvement | 83% (6) | 97% (149) |
| Recovery % reporting improvement | 100% (2) | 91% (23) |
| Pain & inflammation % reporting improvement | 80% (5) | 67% (6) |
| Digestion % reporting improvement | 43% (7) | — |
| Libido % reporting improvement | 0% (3) | 93% (70) |
| Hormones % reporting improvement | 100% (2) | 90% (91) |
| Blood sugar % reporting improvement | 88% (8) | — |
| Heart & lipids % reporting improvement | 100% (3) | 62% (8) |
| Skin & hair % reporting improvement | 33% (3) | 40% (5) |
| Longevity % reporting improvement | — | 50% (2) |
| Common side effects | nausea, fatigue, stomach issues, constipation | suppression, hair loss, acne, water retention |
| Typical dose reported | 2.4 mg / once weekly | 200 mg / weekly |
This study shows that new anti-diabetic drugs, particularly GLP1-RA and Tirzepatide, are the most effective in inducing weight loss in patients with type 2 diabetes. Interestingly, exenatide appears to be the only GLP1-RA that induces a mild weight loss.
Pharmacol Res, 2021 ↗“I've lost 35lbs since then and now I'm in the Healthy range on BMI. My IBSD has virtually disappeared.”
The guidelines also provide recommendations regarding identification of patients, dosing, monitoring, and follow-up. This Practice Pearl will discuss evidence-based testosterone therapy for management of HSDD in postmenopausal women.
Menopause, 2023 ↗“Feel the best I've ever felt in my life. TRT and peptides have been game changers for me!”
Related comparisons
Percentages come from first-hand user reports and are not clinical outcomes. Talk to a doctor before starting, stopping or combining anything. How we rate